|
|
Volumn 32, Issue 1, 2014, Pages 6-7
|
|
Genentech's glyco-engineered antibody to succeed Rituxan.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
MONOCLONAL ANTIBODY;
RITUXIMAB;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METABOLIC ENGINEERING;
NOTE;
T CELL LYMPHOMA;
UNITED STATES;
ANTIBODIES;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
DRUG INDUSTRY;
HUMANS;
LYMPHOMA, T-CELL;
METABOLIC ENGINEERING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84903795824
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0114-6b Document Type: Note |
|
Times cited : (32)
|
|
References (0)
|
